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Abstract
Background: Diastolic dysfunction refers to an impaired relaxation and an abnormality in a heart’s filling during
diastole while left ventricular systolic function is preserved. Diastolic dysfunction is commonly observed in patients
with primary hypertension, diabetes and cardiomyopathies such as hypertrophic cardiomyopathy or restrictive
cardiomyopathy. We have generated a restrictive cardiomyopathy (RCM) mouse model with troponin mutations in
the heart to mimic the human RCM patients carrying the same mutations.
Results: In the present study, we have investigated the ventricular muscle internal dynamics and pressure
developed during systole and diastole by inserting a micro-catheter into the left ventricle of the RCM mice with or
without treatment of desensitizer green tea extracts catechins. Our results demonstrate that green tea catechin is
able to correct diastolic dysfunction in RCM mainly by improving ventricular compliance and reducing the internal
muscle rigidity caused by myofibril hypersensitivity to Ca2+.
Conclusion: Green tea extract catechin is effective in correcting diastolic dysfunction and improving ventricular
muscle intrinsic compliance in RCM caused by troponin mutations.
Keywords: Diastolic dysfunction, Restrictive cardiomyopathy, Calcium desensitization, Green tea extracts,
Pressure-volume relationship, Experimental animals
Background
Diastolic dysfunction refers to an impaired relaxation and
an abnormality in a heart’s filling during diastole while left
ventricular systolic function is preserved. Diastolic dys-
function is a common sign in elderly population and in
patients suffering from primary hypertension and various
cardiomyopathies [1, 2]. For example, both hypertrophic
cardiomyopathy (HCM) and restrictive cardiomyopathy
(RCM) share a common feature of diastolic dysfunction
[3, 4]. Diastolic dysfunction is an important clinical
syndrome since almost half of heart failure patients have
diastolic dysfunction [5–7]. There is a critical need to
understand the mechanisms that cause diastolic dysfunc-
tion and heart failure and to develop target-based inter-
vention and medications to correct the overt condition
and to treat the patients. For the moment, in the absence
of such agents and intervention, treatment of diastolic
dysfunction is difficult and often ineffective [8].
In our previous studies, we have demonstrated that
hypersensitivity of myofibrils to Ca2+ is a key factor associ-
ated with impaired relaxation in the heart [9, 10]. Further-
more, we have demonstrated, for the first time that
desensitization of Ca2+ hypersensitivity in RCM can correct
phenotypes and rescue the RCM mice [11, 12]. In applying
green tea extracts catechins into RCM mice, we have fur-
ther indicated that Ca2+ desensitizer green tea catechins
can reverse diastolic dysfunction in RCM mice with tropo-
nin mutations [13]. However, it is not clear whether cate-
chins correct the impaired relaxation by altering calcium
dynamics or by altering the myofibril protein interactions,
i.e. internal cardiac muscle dynamics. In the present study,
we have determined the internal ventricular muscle dynam-
ics using pressure-volume measurements in left ventricles
in RCM mice with or without treatment of green tea cate-
chins. Furthermore, the calcium handling proteins have
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been analyzed to exclude their effects on Ca2+ dynamics in
RCM myocardial cells. Our results demonstrate that green
tea catechin is able to correct diastolic dysfunction in RCM
mainly by improving ventricular compliance and reducing




RCM cTnI193His transgenic mice (TG) used in this study
were generated in our laboratory by transgenic expres-
sion of cTnI193His mutant protein in the heart under the
α-myosin heavy chain promoter [9]. Wild-type (WT)
C57BL/6 mice were used as controls in the study. Both
TG and WT mice were maintained in animal facilities at
Florida Atlantic University. This investigation was per-
formed in accordance with NIH guidelines, the Guide
for the Care and Use of Laboratory Animals (NIH Pub.
N01-OD-4-2139, 8th edition, 2011) and approved by the
Institutional Animal Care and Use Committees at
Florida Atlantic University.
Treatment of experimental animals
Green tea extract (-)-epigallocatechin-3-gallate (EGCg)
was obtained from Sigma-Aldrich (Catalog number
E4268). The compound was dissolved freshly in 15 %
DMSO (200 mg/ml) as described previously [13]. Both
WT and TG mice (2 months old) were injected intraper-
itoneally daily with EGCg solution (50 mg.kg) (5 days
per week) for 3 months. Each group contained eight
mice. The control mice were injected with the same
amount of 15 % DMSO in a similar manner as described
previously [13].
Cardiac function measurement with high resolution
echocardiography
Cardiac function in experimental mice was examined
and analyzed using a Vevo 770 High-Resolution In Vivo
Imaging System (VisualSonics, Toronto, ON, Canada) in
our laboratory as described previously [9, 14]. To de-
crease experimental bias, all of the echocardiography
measurements were performed by an examiner blinded
to the genotype. Short-axis images were taken to view
the left ventricle (LV) or right ventricle (RV) movement
during diastole and systole. Transmitral blood flow was
observed with Pulse Doppler. All data and images were
saved and analyzed with an Advanced Cardiovascular
Package Software (VisualSonics, Toronto, ON, Canada)
as described previously [9, 14].
Left ventricular pressure–volume analysis
Mice were anesthetized with 3 % isoflurane and were sup-
ported by a ventilator with a maintenance dose of 1 % iso-
flurane after tracheostomy. A research pressure-volume
micro-catheter (1F PV catheter, Millar, Inc. Houston, TX)
was inserted into the left ventricle through the right carotid
artery of the experimental mice. Intra-cardiac pressure (P)
and volume (V) were simultaneously measured and real
time data were displayed and recorded using a P–V con-
ductance system (MPVS Ultra, AD Instruments, Inc. Hous-
ton, TX) coupled to a digital converter (PowerLab, AD
Instruments). Heart rate was continuously monitored using
either ECG electrodes or direct pressure pulses correspond-
ing to each heartbeat. Hemodynamic parameters were mea-
sured under different preloads, which were elicited by
transiently compressing the abdominal inferior vena cava.
The catheter was advanced into the LV to obtain +dP/
dtmax as a measure of systolic function. For diastolic func-
tion, LV end-diastolic pressure (LVEDP), −dP/dtmin, and
Tau were determined. Tau was determined from fitting to
the pressure decay curve from the time when −dP/dtmin
occurs using a zero asymptote. At least eight mice were
measured for each group. In β-adrenergic stimulation assay,
bolus injection of the β-receptor agonist isopretelenol
(1.5 mg/kg body wt). Assays were performed on five TG
and five WT mice.
Western blotting
Cardiac samples were resolved in NuPAGE 4–12 % gradi-
ent BT gels using an Xcell II sure lock Mini Cell gel system
from Invitrogen. The proteins were transferred to a nitro-
cellulose membrane using the Xcell IITM blot module as
described previously [9, 10]. The nitrocellulose membrane
was blocked with 5 % dry fat milk in TBS-T and incubated
with antibodies. The target proteins on immunoblots were
visualized by enhanced chemiluminescence (ECL detection
kit from GE Healthcare). The following primary antibodies
were used: cardiac cTnI 4H6 antibody (1:20000) for cTnI
protein. Rb pAb (phospho s16, 1:20000) was used to deter-
mine the phosphorylated phospholamban. Ms mAb to
SERCA-2 ATPase antibody (1:600) was used to determine
the SERCA-2 proteins. Ms mAb to Phosplamban antibody
(1:20000) was used to determine phospholamban proteins.
The protein bands were scanned by densitometry and
quantified among the samples on the same blot.
Statistical analysis
The results are presented as means ± SE. ANOVA
followed by post hoc Newman–Keuls (SNK) tests and
Student’s t test were used to determine the statistical sig-
nificance. Statistical significance was set as P <0.05.
Results
Diastolic dysfunction is reversed by EGCg treatment in
RCM mice
The data from cardiac function measurements using
high resolution echocardiography in experimental mice
indicate that enlarged left and right atria are significantly
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reduced in RCM mice after the treatment of EGCg (Fig. 1
and Table 1). Left ventricular end diastolic dimension
(LVEDD) is increased in RCM mice after the treatment.
The prolonged left ventricular isovolumentric relaxation
time (IVRT) is significantly shortened in RCM mice after
the treatment with EGCg (Table 1). These results are
consistent with our report in the previous study indicat-
ing that green tea extract EGCg is able to reverse
diastolic dysfunction and improve cardiac relaxation in
RCM mice.
EGCg corrects diastolic dysfunction by reducing cardiac
muscle internal rigidity and increasing ventricular
compliance in RCM mice
Mouse left ventricular function was assessed using cath-
eter based P-V loop measurements. The measurements
exhibit the P-V loops of each mouse ventricle showing
the volume-dependent pressure changes (Fig. 2a and b).
These data indicate that the blood filling in the diastole
stage is limited in RCM mice and the situation is im-
proved in the RCM mice after the treatment with EGCg
(Fig. 2b). Furthermore, we analyzed the pressure volume
relationship (PVR) at end systole (upper line) and end
diastole (Lower line) in Fig. 2a since the PVR at end sys-
tole or end diastole reflects the muscle internal contrac-
tion or relaxation status without the influence of the
volume changes. Our data indicate that no significant
changes are observed in end systole PVR (ESPVR) be-
tween WT and RCM mice before and after the treatment
of EGCg. However, a significant change, increase, has
been observed in RCM mice compared to the WT mice
(Fig. 2a). After the treatment of EGCg, the increased end
diastole PVR (EDPVR) is significantly reduced (Fig. 2a).
These data indicate that increased left ventricular pres-
sure in RCM is caused by the increased ventricular
muscle internal pressure and green tea extract EGCg is
Fig. 1 Determination of cardiac function with high resolution echocardiography in WT and RCM TG mice with or without treatment of EGCg. a
Representative two-dimensional short axis views obtained from four different groups of the experimental mice. b Representative M-mode images
and parameter calculation in experimental mice. c Representative images of pulsed Doppler of mitral inflow obtained from the experimental mice.
LV left ventricle, RV right ventricle, E peak velocity of mitral blood inflow in early diastole, A peak velocity of mitral blood inflow in late diastole; E/A ratio;
IVRT isovolumic relaxation time; IVCT isovolumetric contraction time, LVID:s left ventricular internal diameter end systole, LVID:d left ventricular internal
diameter end diastole
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able to reverse the increased ventricular internal pres-
sure and improve diastolic function in RCM mice. Fur-
ther analyses of systolic parameters such as ejection
fraction (EF)(Fig. 2c), dp/dt max (Fig. 2d) and ESPVR
(Fig. 2e) indicate that no significant changes have been
observed in systolic function between WT and RCM
mice before and after the treatment of EGCg. However,
diastolic parameters such as –dp/dt min (Fig. 2f ), Tau
(Fig. 2g) and EDPVR (Fig. 2h) are significantly altered in
RCM mice compared to WT mice and EGCg can cor-
rect the changed diastolic parameters in RCM mice.
β-adrenergic stimulation cannot change cardiac filling
and diastolic function in RCM
We have further tried to determine the effect of β-
adrenergic stimulation in RCM mice by injection of iso-
proterenol (ISO) in tested mice. The data indicate that
ISO treatment cannot increase the heart filling and has
no effect on LVDP in RCM mice (Fig. 3a, b and c). How-
ever, ISO can stimulate heart rate (HR)(Fig. 3d), increase
ejection fraction (EF)(Fig. 3e) and maximum contractility
(Fig. 3f ) in both WT and RCM mice, suggesting that
ISO cannot change the internal muscle rigidity and can-
not improve diastolic function in RCM mice.
EGCg treatment does not alter Ca2+ handling proteins
and their phosphorylation status
Western blotting data indicate that the levels of the
tested Ca2+ handling proteins do not show any signifi-
cant changes both in WT and RCM mice after the treat-
ment of green tea extract EGCg (Fig. 4). These proteins
include the sarcoendoplasmic reticulum calcium trans-
port ATPase (SERCA2), phospholamban (PLN) and
phosphorylated phospholamban (phosphor-PLN). These
Table 1 Cardiac function measurements on WT and RCM TG mice
WT control WT EGCg RCM control RCM EGCg
Parameters
Body weight (g) 31.67 ± 1.53 30.67 ± 1.61 27.25 ± 1.21* 28.35 ± 1.28*
Heart rate (bpm) 470.72 ± 38.12 481.37 ± 44.15 450.75 ± 50.76 460.17 ± 49.73
Atria
LAEDD (mm) 2.12 ± 0.02 2.13 ± 0.03 2.29 ± 0.04** 2.21 ± 0.05*‡
LAESD (mm) 1.67 ± 0.03 1.69 ± 0.04 1.74 ± 0.06 1.71 ± 0.05
RAEDD (mm) 2.11 ± 0.05 2.12 ± 0.06 2.31 ± 0.11** 2.26 ± 0.05*
RAESD (mm) 1.71 ± 0.06 1.69 ± 0.03 1.64 ± 0.04 1.68 ± 0.05
LV end diastole
IVS (mm) 0.75 ± 0.04 0.76 ± 0.03 0.75 ± 0.04 0.74 ± 0.03
LVEDD (mm) 3.88 ± 0.07 3.85 ± 0.04 3.42 ± 0.0 6* 3.62 ± 0.03*‡
LV PW (mm) 0.76 ± 0.02 0.75 ± 0.04 0.76 ± 0.03 0.73 ± 0.03
LV Volume (μl) 64.67 ± 1.71 63.95 ± 2.16 46.16 ± 2.24** 55.92 ± 1.19*‡
LV end systole
IVS (mm) 1.27 ± 0.03 1.27 ± 0.04 1.24 ± 0.02 1.25 ± 0.03
LVESD (mm) 2.05 ± 0.05 2.08 ± 0.06 1.58 ± 0.02** 1.75 ± 0.03*‡
LV PW (mm) 1.22 ± 0.03 1.22 ± 0.04 1.21 ± 0.03 1.21 ± 0.02
LV Volume (μl) 13.03 ± 0.43 13.42 ± 0.61 5.96 ± 0.71 9.35 ± 0.80**ǂǂ
Ejection Fraction (%) 79.85 ± 1.41 79.01 ± 1.00 80.33 ± 1.91 80.57 ± 2.16
Fractional Shortening (%) 46.72 ± 1.22 45.38 ± 0.66 47.95 ± 1.84 47.44 ± 2.33
Mitral Doppler
E (mm/s) 827.61 ± 22.05 829.75 ± 24.22 740.81 ± 18.93* 809.04 ± 25.14
A (mm/s) 657.95 ± 12.34 667.35 ± 16.48 560.33 ± 33.66 * 633.57 ± 26.83
E/A 1.26 ± 0.04 1.24 ± 0.02 1.32 ± 0.05 1.27 ± 0.05
IVRT (ms) 16.41 ± 0.44 16.44 ± 0.46 21.43 ± 0.54** 18.53 ± 0.51*‡
IVCT (ms) 10.58 ± 0.33 11.05 ± 0.29 10.36 ± 0.75 10.86 ± 0.53
Values are expressed as means ± SE for each group. LA left atrium, RA right atrium, LV left ventricle, EDD end diastolic dimension, ESD end systolic dimension, PW posterior
wall thickness of LV, IVS intra-ventricular septum, EF ejection fraction of LV, FS fractional shortening of LV, E mitral Doppler E peak velocity, A mitral Doppler A peak velocity,
IVRT isovolumetric relaxation time, IVCT isovolumetric contraction time. Statistical significance was determined by ANOVA followed by post hoc Newman-Keuls (SNK) tests
*p <0.05 compared to WT control, **p <0.01 compared to WT control; ǂp <0.05 compared to RCM control; ǂǂp <0.01 compared to RCM control
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Fig. 2 Representative pressure-volume loops obtained from catheter-based left ventricular P-V measurements in experimental mice. a Characteristic
changes in left ventricular developmental pressure (LVDP) corresponding to the volume changes. Upper line indicates end systole pressure volume
relationship (ESPVR) and the low line indicates end diastole pressure volume relationship (EDPVR) in different groups of mice: 1, WT mice in control
group (WT control); 2, WT mice with EGCg treatment (WT EGCg); 3, cTnI193His RCM mice in control (cTnI193His control); 4, cTnI193His RCM with
EGCg treatment (cTnI193His EGCg). b Normal baseline PV loops from different groups of mice. Cardiac function parameters are shown in (c),
ejection fraction (EF); (d) the maximal rate of contraction (+dP/dt); (e) end-systolic pressure–volume relation slope (ESPVR); (f) the maximal rate
of relaxation (−dP/dt); (g) relaxation time constant calculated by Weiss method (τ); (h) end-diastolic pressure–volume relation (EDPVR). Data are presented
as means ± SE. *compared between WT and TG mice; ǂ compared between mice with or without treatment. * or ǂP <0.05; ** or ǂǂ P<0.01
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data suggest that green tea extract EGCg corrects dia-
stolic dysfunction and improve cardiac relaxation in
RCM not via the alteration in Ca2+ handling protein and
Ca2+ concentration in myocardial cells.
Discussions
Heart failure (HF) is the leading cause of mortality in
the United States [1]. In two major types of HF, HF with
reduced ejection fraction (HFrEF) and HF with pre-
served ejection fraction (HFpEF), prevalence of HFpEF
is rising, with mortality, morbidity, and healthcare costs
now equal to those for HFrEF [2, 5, 15]. However, the
pathophysiology of HFpEF is poorly understood, and no
medication trials have had positive effects on their
primary end-points. A major cause of HFpEF is diastolic
dysfunction which is commonly seen in primary hyper-
tension and various cardiomyopathies such as HCM and
RCM. Diastolic dysfunction occurs when the ventricles
cannot fill normally, and in severe conditions, it can lead
to diastolic heart failure (DHF). Recently studies have re-
vealed that cardiac diastolic dysfunction increases with
advancing age, approximately 30–40 % of the population
(aged 45 or older) had diastolic dysfunction, and nearly
half of them were healthy individuals [16–18].
In the present study, we have further confirmed that
diastolic dysfunction occurs in RCM mice with troponin
mutations in the heart and desensitizing green tea ex-
tract EGCg can reverse the diastolic dysfunction in
Fig. 3 Inotropic responses to β-adrenergic stimulation in WT and cTnI193His RCM mice. Representative pressure-volume loops recorded at baseline
(solid curve) and after administration of isoproterenol (ISO; dashed curve) in WT mice (a) and in cTnI193His RCM mice (b). c Left ventricular developed
pressure (LVDP); (d) the heart rate (HR); (e) Ejection fraction (EF); (f) the maximal rate of contraction (+dP/dt max). Data are presented as means ± SE.
*Significant difference compared between before and after ISO stimulation. * P <0.05
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RCM hearts. Using micro-catheter based P-V loop mea-
surements in both WT and RCM TG mice, we have suc-
cessfully analyzed P-V loops and end diastolic pressure
and volume relationship (EDPVR) in the experimental
mice. The P/V index reflects the elastance of the left
ventricles. The P/V plus dP/dt are common physiologic
measurement of cardiac tissues. EDPVR is an index that
reveals the internal ventricular muscle dynamics and de-
veloped pressure in diastole. Our data indicate that the
EDPVR increased significantly in RCM heart compared
to the WT hearts, suggesting an increased ventricular
muscle internal pressure (force) that is Ca2+ independent
in RCM hearts with troponin mutations. The increased
ventricular muscle internal pressure (force) causes a
rigid ventricle and enlarged left atrium or both atria,
which are consistent with what we reported previously
of cellular and morphological examination on the same
RCM mice [10, 11]. Green tea desensitizing EGCg is able
to reverse the diastolic dysfunction in RCM mice be-
cause it can correct the increased EDPVR in these mice
without any significant effects on Ca2+ dynamics in myo-
cardial cells by altering Ca2+ handling proteins or their
phosphorylation status.
This is the first study investigating the ventricular
muscle internal dynamics and pressure developed during
diastole in RCM hearts with troponin mutations. It is
also novel to demonstrate that green tea desensitizing
EGCg reverse diastolic dysfunction by correcting the in-
ternal EDPVR in the RCM hearts. It is interesting to
note that a beta-adrenergic agonist has barely any effect
on diastolic function and heart filling although it can in-
crease heart rate and ejection fraction in RCM mice.
The results from this study and our previous studies indi-
cate that myofibril hypersensitivity is a key factor that
causes impaired relaxation in HCM or RCM hearts associ-
ated with myofibril protein troponin mutations in myocar-
dial cells. Green tea extract EGCg can reverse the impaired
relaxation by correcting the hypersensitivity-induced abnor-
mal ventricular muscle internal pressure in RCM hearts.
Recently, the desensitization effect of green tea extracts has
been further confirmed in cells from a patient with HCM
[19]. The effect of green tea extracts occurs in internal ven-
tricular muscle dynamics by interfering with calcium bind-
ing to troponin C in myocardial cells [20], and probably not
by altering calcium dynamics through changes in calcium
handling protein concentrations or their activities. How-
ever, one in vitro study using isolated murine cardiomyo-
cytes reported that nanomolar EGCG could increase
calcium transients [21]. Further studies are needed to clarify
the effects of EGCG on calcium dynamics. In addition, it
should be pointed out that diastolic dysfunction covers a
vast range of etiology and causes, and green rea
desensitization may not be so effective when it is applied to
some types of diastolic dysfunction such as those related to
fibrosis or amyloidosis.
Conclusion
Green tea extract catechin is effective in correcting dia-
stolic dysfunction and improving ventricular muscle in-
trinsic compliance in RCM caused by troponin mutations.
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